Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational Data Cannabis DEA 52

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2(a), Oct. 21, 1998 , 112 Stat. 2681–759 ; Pub.

Banking 45

Banking Law Marijuana State Laws 45